Start Over

Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model

Authors :: Mylène Bernes
Fabrice Navarro
Claudia Cabella
Isabelle Texier
Gunter Almer
Laurent Devel
Harald Mangge
Ruth Prassl
Fabrice Beau
Paolo Oliva
Service d'Ingénierie Moléculaire pour la Santé (ex SIMOPRO) (SIMoS)
Médicaments et Technologies pour la Santé (MTS)
Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
ANR-17-EURE-0003,CBH-EUR-GS,CBH-EUR-GS(2017)
Source :: Molecules, Molecules, 2019, 24 (19), pp.3499. ⟨10.3390/molecules24193499⟩, Molecules, Vol 24, Iss 19, p 3499 (2019), Volume 24, Issue 19
Publication Year :: 2019
Abstract: Atherosclerosis is a major cardiovascular disease worldwide, that could benefit from innovative nanomedicine imaging tools and treatments. In this perspective, we here studied, by fluorescence imaging in ApoE-/- mice, the biodistribution of non-functionalized and RXP470.1-targeted nanostructured lipid carriers (NLC) loaded with DiD dye. RXP470.1 specifically binds to MMP12, a metalloprotease that is over-expressed by macrophages residing in atherosclerotic plaques. Physico-chemical characterizations showed that RXP-NLC (about 105 RXP470.1 moieties/particle) displayed similar features as non-functionalized NLC in terms of particle diameter (about 60-65 nm), surface charge (about &minus<br />5 &mdash<br />&minus<br />10 mV), and colloidal stability. In vitro inhibition assays demonstrated that RXP-NLC conserved a selectivity and affinity profile, which favored MMP-12. In vivo data indicated that NLC and RXP-NLC presented prolonged blood circulation and accumulation in atherosclerotic lesions in a few hours. Twenty-four hours after injection, particle uptake in atherosclerotic plaques of the brachiocephalic artery was similar for both nanoparticles, as assessed by ex vivo imaging. This suggests that the RXP470.1 coating did not significantly induce an active targeting of the nanoparticles within the plaques. Overall, NLCs appeared to be very promising nanovectors to efficiently and specifically deliver imaging agents or drugs in atherosclerotic lesions, opening avenues for new nanomedicine strategies for cardiovascular diseases.